他汀类药物对癌症患者预后的 Meta 分析(英文)

目的：系统评价癌症患者服用他汀类药物后对疾病预后的作用。方法：利用计算机检索Cochrane Library， PubMed和EMbase数据库，收集这些数据库中从建库至2015年3月公开发表的有关他汀类药物和癌症预后的文章，采 用Stata 12.0软件进行Meta分析。结果：共纳入25篇文献，523 193例患者。Meta分析结果显示：与未服用他汀类药物的 癌症患者相比，服用他汀类药物的癌症患者的总体死亡危险比(hazard ratio，HR)为0.82(95% CI：0.76~0.89)。亚组分析 结果显示前列腺癌症患者死亡的HR为0.66(95% CI：0.52~0.83)。敏感性分析显示在排除随访时间<5年的文献后，服用 他汀类药物的癌症患者的死亡HR为0.91(95% CI：0.75~1.10)。结论：他汀类药物能在一定程度上降低癌症患者的病死 率，但其远期作用还需要进一步研究确认。

Prognostic value of statin for cancer patients: A Meta-analysis

Objective: To systematically evaluate the eff ect of statins on prognosis for patients with cancers. Methods: Literature on PubMed, EMbase and Cochrane library was screened from the establishment of databases to March, 2015 to find relevant studies. Random-effects models were used to calculate the pooled hazard ratios (HR) and 95% confidence interval (CI) for the association between statin use and all-cause mortality and cancer-specifi c mortality. Results: A total of 25 studies covered 523 193 patients were identifi ed and included in this Meta- analysis. The pooled effect showed that statin application was associated with a reduction in all- cause mortality in cancer patients (HR, 0.82; 95% CI: 0.76 to 0.89). A significantly decreased mortality in prostate cancer was revealed in subgroup by cancer sites (HR, 0.66; 95% CI: 0.52 to 0.83). In addition, sensitivity analysis demonstrated a weakened association between statin application and all-cause mortality aft er excluding the studies with shorter follow-up duration (HR, 0.91; 95% CI: 0.75 to 1.10). Conclusion: A beneficial effect of statin on all-cause mortality and cancer-specific mortality is presented in patients with cancer. However, further studies are needed to confirm the long term eff ect.